These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35348393)

  • 41. Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study.
    Strasberg SM; Dehdashti F; Siegel BA; Drebin JA; Linehan D
    Ann Surg; 2001 Mar; 233(3):293-9. PubMed ID: 11224615
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Value of
    Zhou N; Guo X; Sun H; Yu B; Zhu H; Li N; Yang Z
    Front Oncol; 2021; 11():714948. PubMed ID: 34858808
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Preoperative staging of liver metastases from uveal melanoma by magnetic resonance imaging (MRI) and fluorodeoxyglucose-positron emission tomography (FDG-PET).
    Servois V; Mariani P; Malhaire C; Petras S; Piperno-Neumann S; Plancher C; Levy-Gabriel C; Lumbroso-le Rouic L; Desjardins L; Salmon RJ
    Eur J Surg Oncol; 2010 Feb; 36(2):189-94. PubMed ID: 19775851
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of ¹⁸F-FDG-PET in decision making for liver metastectomy of colorectal cancer.
    McLeish AR; Lee ST; Byrne AJ; Scott AM
    ANZ J Surg; 2012; 82(1-2):30-5. PubMed ID: 22507492
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment.
    Niekel MC; Bipat S; Stoker J
    Radiology; 2010 Dec; 257(3):674-84. PubMed ID: 20829538
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The role of FDG-PET in the selection of patients with colorectal liver metastases.
    Wiering B; Krabbe PF; Dekker HM; Oyen WJ; Ruers TJ
    Ann Surg Oncol; 2007 Feb; 14(2):771-9. PubMed ID: 17086488
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A comparison of diagnostic imaging modalities for colorectal liver metastases.
    Bonanni L; de'Liguori Carino N; Deshpande R; Ammori BJ; Sherlock DJ; Valle JW; Tam E; O'Reilly DA
    Eur J Surg Oncol; 2014 May; 40(5):545-550. PubMed ID: 24491289
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Improved long-term survival after resection of colorectal liver metastases following staging with FDG positron emission tomography.
    Abbadi RA; Sadat U; Jah A; Praseedom RK; Jamieson NV; Cheow HK; Whitley S; Ford HE; Wilson CB; Harper SJ; Huguet EL
    J Surg Oncol; 2014 Sep; 110(3):313-9. PubMed ID: 24737685
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of PET-CT on disease recurrence and management in patients with potentially resectable colorectal cancer liver metastases. Long-term results of a randomized controlled trial.
    Serrano PE; Gu CS; Moulton CA; Husien M; Jalink D; Martel G; Tsang ME; Hallet J; McAlister V; Gallinger S; Levine M
    J Surg Oncol; 2020 May; 121(6):1001-1006. PubMed ID: 32034769
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Preoperative imaging for colorectal liver metastases: a nationwide population-based study.
    Elfrink AKE; Pool M; van der Werf LR; Marra E; Burgmans MC; Meijerink MR; den Dulk M; van den Boezem PB; Te Riele WW; Patijn GA; Wouters MWJM; Leclercq WKG; Liem MSL; Gobardhan PD; Buis CI; Kuhlmann KFD; Verhoef C; Besselink MG; Grünhagen DJ; Klaase JM; Kok NFM;
    BJS Open; 2020 Aug; 4(4):605-621. PubMed ID: 32374497
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The use of FDG-positron emission tomography for the evaluation of colorectal metastases of the liver.
    Boykin KN; Zibari GB; Lilien DL; McMillan RW; Aultman DF; McDonald JC
    Am Surg; 1999 Dec; 65(12):1183-5. PubMed ID: 10597072
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of multiphase CT, FDG-PET and intra-operative ultrasound in patients with colorectal liver metastases selected for surgery.
    Wiering B; Ruers TJ; Krabbe PF; Dekker HM; Oyen WJ
    Ann Surg Oncol; 2007 Feb; 14(2):818-26. PubMed ID: 17136470
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Additional value of FDG-PET/CT in management of "solitary" liver metastases: preliminary results of a prospective multicenter study.
    Grassetto G; Fornasiero A; Bonciarelli G; Banti E; Rampin L; Marzola MC; Massaro A; Galeotti F; Del Favero G; Pasini F; Minicozzi AM; Al-Nahhas A; Cordiano C; Rubello D
    Mol Imaging Biol; 2010 Apr; 12(2):139-44. PubMed ID: 19626378
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of FDG PET/CT in patients with colorectal cancer metastases.
    Kochhar R; Liong S; Manoharan P
    Cancer Biomark; 2010; 7(4):235-48. PubMed ID: 21576816
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fluorine-18-fluorodeoxyglucose positron emission tomography as an objective substitute for CT morphologic response criteria in patients undergoing chemotherapy for colorectal liver metastases.
    Nishioka Y; Yoshioka R; Gonoi W; Sugawara T; Yoshida S; Hashimoto M; Shindoh J
    Abdom Radiol (NY); 2018 May; 43(5):1152-1158. PubMed ID: 28815337
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of Fluorodeoxyglucose PET/Computed Tomography on the Management of Patients with Colorectal Cancer.
    Laurens ST; Oyen WJ
    PET Clin; 2015 Jul; 10(3):345-60. PubMed ID: 26099671
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Economic evaluation of 18F-FDG PET/CT, MRI and CE-CT in selection of colorectal liver metastases eligible for ablation - A cost-effectiveness analysis.
    Schnitzer ML; Buchner J; Biechele G; Grawe F; Ingenerf M; von Münchhausen N; Kaiser CG; Kunz WG; Froelich MF; Schmid-Tannwald C; Rübenthaler J
    Eur J Radiol; 2023 Jun; 163():110803. PubMed ID: 37004464
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [
    Bak-Fredslund KP; Keiding S; Villadsen GE; Kramer S; Schlander S; Sørensen M
    Liver Int; 2020 Feb; 40(2):447-455. PubMed ID: 31705784
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
    Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T
    Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of preoperative whole-body positron emission tomography with MDCT in patients with primary colorectal cancer.
    Akiyoshi T; Oya M; Fujimoto Y; Kuroyanagi H; Ueno M; Yamaguchi T; Koyama M; Tanaka H; Matsueda K; Muto T
    Colorectal Dis; 2009 Jun; 11(5):464-9. PubMed ID: 18637927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.